GISTs are solid tumors, primarily in the stomach, characterized by KIT and EGFR mutations, with Gleevec as a key treatment. Recent advancements in GIST treatment include multiple TKIs, such as Sutent, ...

A total of 53 patients with advanced non-GIST soft tissue sarcomas received sunitinib 37.5 mg daily. Primary end point was Response Evaluation Criteria in Solid Tumors defined response. Secondary end ...

Gastrointestinal stromal tumors (GISTs) are growths that form in the digestive tract. The overall GIST survival rate for 5 years is 85%. However, this rate cannot predict the survival of any ...

A recent study offering a comprehensive view of the genome and transcriptome of gastrointestinal stromal tumors (GISTs) has introduced a new, multi-omics-based molecular classification of these tumors ...

We describe a 24-year-old woman from Yemen with no special habits of medical importance. Her first pregnancy aborted spontaneously in the second trimester (January 2007). Afterward she reported ...

A systematic review finds that diagnostic discordance in bone and soft tissue sarcoma may reduce survival, supporting expert second opinions.